[October 02, 2015]

Acceleron Announces Presentation of Sotatercept Data at the American Society of Nephrology Kidney Week 2015

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported that its collaboration partner, Celgene, and investigators on the sotatercept program will present preclinical and interim clinical data at the American Society of Nephrology (ASN) Kidney Week 2015, being held in San Diego, CA (News - Alert) on November 3-8, 2015.

Preliminary data from ongoing Phase 2a clinical studies of sotatercept in End-Stage Kidney Disease patients, including effects on hemoglobin, vascular calcification, bone mineral density and safety and tolerability, will be presented on Thursday and Friday, November 5 and 6, 2015. Additionally, data from preclinical studies will be presented on Friday and Saturday, November 6 and 7, 2015.

Thursday, November 5, 2015, from 10:00 AM - 12:00 PM (PST)

• "Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients With End-Stage Kidney Disease on Hemodialysis" (clinical poster presentation (TH-PO038))

Friday, November 6, 2015, from 4:30 PM - 6:30 PM (PST)

• "Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis Subjects: Interim Analysis of a Phase 2 Study" (clinical oral presentation (FR-OR020))
• "The Role of Activin in the CKD-MBD" (preclinical oral presentation (FR-OR021))

Saturday, November 7, 2015 from 10:00 AM - 12:00 PM (PST)

• "Kidney Injury/Repair Stimulates Vascular Disease Through Activin and Systemic Wnt Inhibition" (preclinical poster presentation (SA-PO1068))

The clinical presentations will be available on Acceleron's website (www.acceleronpharma.com) in the "Publications" tab when presented at Kidney Week 2015.

About Sotatercept

Sotatercept is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-ß) superfamily involved in the late stages of erythropoiesis (red blood cell production). Sotatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing sotatercept as part of a global collaboration. Sotatercept is currently in multiple phase 2 clinical trials. For more information, please visit www.clinicaltrials.gov.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-beta) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical therapeutic candidates with novel mechanisms of action. These therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151002005405/en/

[ Back To TMCnet.com's Homepage ]